angiotensin renin system blockade

Description Results NMA

Stroke 0.58 [0.37; 0.90]

microvascular events 0.65 [0.46; 0.91]

All deaths 0.83 [0.65; 1.06]

Fatal and nonfatal MI 0.80 [0.60; 1.05]

tight control of blood pressure aiming at a BP <150/85 (with the use of captopril or atenolol as main treatment, other treatment were added if the control criteria were not met) (n=758)

vs.

less tight control aiming at a blood pressure of <180/105 (avoiding treatment with ACE inhibitors or beta-blockers) (n=390)

open

Parallel groups

Sample size: 758/390

Primary endpoint: not unique (3)

FU duration: 8.4y (median)

All deaths 1.14 [0.83; 1.55]

Stroke 1.38 [0.74; 2.57]

Fatal and nonfatal MI 1.19 [0.83; 1.69]

microvascular events 1.28 [0.81; 2.03]

captopril 25 mg/d aiming at a BP <150/85 (n=400)

vs.

atenolol 50mg/d aiming at a BP <150/85 (n=358)

open

Parallel groups

Sample size: 400/358

Primary endpoint: not unique (3)

FU duration: ND

All deaths 0.54 [0.31; 0.95]

Cardiovascular events 0.59 [0.38; 0.91]

Fatal and nonfatal MI 0.38 [0.20; 0.73]

Cardiovascular death 0.48 [0.21; 1.10]

Stroke 1.03 [0.57; 1.85]

Captopril initial dose of 50 mg daily given in one or two doses (n=309)

vs.

thiazide diuretic or beta-blocker (n=263)

open with blinded assessment

Parallel groups

Sample size: 309/263

Primary endpoint: CV events

FU duration: 6.1 year

microvascular events 0.30 [0.14; 0.64]

microvascular events 0.80 [0.66; 0.97]

All deaths 0.92 [0.69; 1.23]

Cardiovascular events 0.91 [0.72; 1.15]

irbesartan 150 mg daily (n=195)

vs.

placebo (n=201)

3 arms trial: irbesartan 150 and 300 mg daily, placebo

double-blind

Parallel groups

Sample size: 195/201

Primary endpoint: diabetic nephropathy

FU duration: 2 years

Irbesartan 300 mg daily (n=579)

vs.

placebo (n=569)

double blind

Parallel groups

Sample size: 579/569

Primary endpoint: renal death

FU duration: 2.6 years

microvascular events 0.77 [0.63; 0.94]

All deaths 1.04 [0.77; 1.40]

Cardiovascular events 1.03 [0.81; 1.31]

Irbesartan 300 mg daily (n=579)

vs.

amlodipine 10 mg daily (n=567)

double blind

Parallel groups

Sample size: 579/567

Primary endpoint: renal death

FU duration: 2.6 years

All deaths 0.99 [0.89; 1.10]

Stroke 1.06 [0.89; 1.26]

Fatal and nonfatal MI 1.03 [0.94; 1.13]

Cardiovascular events 1.07 [0.99; 1.15]

lisinopril 10 to 40 mg/d (n=2431)

vs.

chlorthalidone 12.5 to 25 mg/d (n=4498)

double-blind

Parallel groups

Sample size: 2431/4498

Primary endpoint: fatal CHD or nonfatal MI

FU duration: 4.9 y

microvascular events 0.79 [0.66; 0.95]

All deaths 1.02 [0.80; 1.30]

losartan 50 to 100 mg once daily (n=751)

vs.

placebo (n=762)

double-blind

Parallel groups

Sample size: 751/762

Primary endpoint: doubling of the creatinine, end-stage renal disease, death

FU duration: 3.4 y

onset of microalbuminuria 0.77 [0.63; 0.94]

CV death 4.96 [1.44; 17.12]

all cause death 1.72 [0.91; 3.24]

non fatal stroke 1.74 [0.73; 4.13]

non fatal MI 0.65 [0.35; 1.19]

CV events 0.88 [0.63; 1.23]

all cause death 0.96 [0.52; 1.75]

CV death 3.36 [0.93; 12.07]

non fatal stroke 0.73 [0.30; 1.79]

non fatal MI 0.43 [0.11; 1.65]

olmesartan at 40 mg/day (n=2232)

vs.

placebo (n=2215)

double-blind

Parallel groups

Sample size: 2232/2215

Primary endpoint: microalbuminuria

FU duration: 3.2 y

olmesartan (n=282)

vs.

placebo (n=284)

double-blind

Parallel groups

Sample size: 282/284

Primary endpoint:

FU duration: